Biotechnology

Thursday Jun 10, 2021 - 12:43 pm

InvestorNewsBreaks – Healthy Extracts Inc.’s (HYEX) HERHEART(TM) Packs a ‘Whole Host of Health Benefits’

Healthy Extracts (OTCQB: HYEX), through its wholly owned subsidiary BergaMet NA(TM), has developed HERHEART(TM), an exclusive supplement scientifically formulated specifically for women to improve perimenopausal symptoms and cardiovascular health. The supplement’s development was influenced by the statistic that cardiovascular disease is the leading cause of death in women globally. A recent article notes, “A 2020 clinical study revealed that HERHEART reduced mood swings and hot…

Thursday Jun 10, 2021 - 12:36 pm

InvestorNewsBreaks – United Medical Equipment Business Solutions Network Inc. Expands Medication Management App with GoodRX

United Medical Equipment (“UME,” “UMEBSNI”) helps families with resources and provides a network of reliable solutions such as the Medication Management App. Available on both iOS and Android, the app is designed to provide direct and indirect patient care and education for care professionals, caregivers, students, and family members. “GoodRX is the newest addition to the app’s functions,” reads a recent article. “This feature allows…

Wednesday Jun 09, 2021 - 12:22 pm

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Aims for New Standard of Care in Visualizing Cancer

Imagin Medical’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging System(TM) is designed to enhance tumor visualization and resection, potentially lowering recurrence rates. With a focus on establishing a new standard of care in the visualization of cancer during minimally invasive procedures, Imagin Medical is initially targeting bladder cancer, the sixth most prevalent cancer in the U.S. and the third most common in men. Imagin’s i/Blue Imaging…

Tuesday Jun 08, 2021 - 11:41 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) Announces Participation at Ladenburg Thalmann Healthcare Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, will be presenting at the upcoming Ladenburg Thalmann Healthcare Conference. The all-virtual conference is scheduled for July 13–14, 2021. Tryp chair and CEO Greg McKee, president and chief science officer Jim Gilligan and CFO Luke Hayes will participate in the…

Tuesday Jun 08, 2021 - 10:07 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Issues Update on Timely Progression of Psychedelic Medicine Program

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that its GMP mescaline synthesis program is on schedule with the completion of initial production batches. According to the update, the industrial-scale manufacture of pharmaceutical-grade psychedelic compounds, including mescaline and psilocybin, is an important part of XPhyto's psychedelic medicine program and will provide a foundation for its drug formulation and clinical validation work. “With both…

Friday Jun 04, 2021 - 10:35 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Filling EEG Testing Gap in Pediatric Brain Diagnostics

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, was the subject of a feature piece published by Med-Tech News, a publication covering medical devices and manufacturing. The article, authored by the marketing director of BRSF, Irina Nazarova, noted that the need for EEG devices within the pediatric segment often went unmet, even though children can suffer from a number…

Wednesday Jun 02, 2021 - 1:39 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Nears Dosing of Phase 2 Patients with Standout Anthracycline Therapy

CNS Pharmaceuticals (NASDAQ: CNSP) is focused on producing a treatment that improves on the effectiveness of established chemotherapy drug lomustine in increasing overall survival rates of glioblastoma multiforme (“GBM”) patients. GBM is an illness that is nearly 100% fatal in patients just over a year after diagnosis. CNS Pharmaceuticals’ lead drug candidate, Berubicin, has been granted investigational new drug (“IND”) status after promising findings. “Berubicin…

Wednesday Jun 02, 2021 - 1:30 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Building Strong Commercial Pipeline for Unique PeDAL(TM) Platform

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, continues to create value for a growing customer base through its subsidiaries. Researchers from one such subsidiary, Helomics, recently completed key sequencing milestones for ovarian cancer to help build its AI-driven models of the disease. “We are building a strong commercial pipeline for our unique Patient-cEntric…

Tuesday Jun 01, 2021 - 12:39 pm

InvestorNewsBreaks – InvestorBrandNetwork, BioMedWire to Collaborate with Q1 Productions for Slate of Upcoming Events

InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, today announced that it will collaborate with Q1 Productions as an official media sponsor for its full event lineup in 2021. IBN also announced that BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of the 50+ brands part of the InvestorBrandNetwork, will also be joining as an official media sponsor for…

Tuesday Jun 01, 2021 - 11:28 am

InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Completes Initial Shipment for Major Plant-Based Medicine Trial

RYAH Group (CSE: RYAH) today announced that it has completed the first shipment of the RYAH Smart Dry Herb Inhalers, which includes a delivery of approximately 10,000 RYAH Cartridges and QR Codes to an international clinic undertaking one of the world’s largest and most comprehensive clinical trials in plant-based medicine. The initial shipment is designated to be used by the clinic in a pilot run…

Friday May 28, 2021 - 12:34 pm

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Potential Expansion of ‘Covid-ID Lab’

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently received the CE-IVD approval (European certification) of its 25-minute COVID-19 RT-PCR test kits (“Covid-ID Lab”). The approval facilitated initial sale and distribution of the Covid-ID Lab in Germany and, later, other parts of Europe, the Middle East and North America. The company also recently announced delivery of 2,000 units of Covid-ID Lab…

Thursday May 27, 2021 - 11:58 am

InvestorNewsBreaks – Healthy Extracts Inc.’s (HYEX) Leading Products Backed by Research, Clinical Studies

Healthy Extracts (OTCQB: HYEX), through its two subsidiaries, BergaMet NA(TM) and Ultimate Brain Nutrients(TM) (“UBN”), is focused on the research, development and sale of natural plant-based formulations offering benefits for cardiovascular and neuro health. The targeting of these two high-growth categories reflects Healthy Extracts’ commitment to strengthening its position in the multibillion nutraceuticals market. “Research and clinical studies show positive results for two leading products…

Wednesday May 26, 2021 - 1:25 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Study Promising Candidate in Phase 2 GBM Trial

CNS Pharmaceuticals (NASDAQ: CNSP) is on track to begin a potentially pivotal Phase 2 trial during the second quarter of 2021. This trial of CNSP’s lead drug candidate, Berubicin, in the treatment of glioblastoma multiforme (“GBM”) is currently planned to include up to 243 subjects, randomized 2:1 (162 Berubicin/81 Lomustine) with an interim analysis when 50% of the subjects reach six months in the study.…

Wednesday May 26, 2021 - 1:12 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Adds Insight, Strengthens Positioning Through Strategic Board Appointment

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently expanded its board of directors with the appointment of Dr. Christina Jenkins. Dr. Jenkins holds capital markets expertise coupled with health care experience through roles that span clinical medicine, venture capital, health plans, and health care systems. Her unique skillset, multivariate perspective and extensive experience…

Wednesday May 26, 2021 - 1:01 pm

InvestorNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Breakthrough Cancer Visualization Technology Holds Significant Potential

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is looking to change how cystoscopies for bladder cancer are performed with the goal of potentially lowering recurrence rates and ultimately helping improve patients’ lives and long-term outlook. “The company’s i/Blue Imaging System(TM) is a breakthrough cancer visualization technology currently in the manufacturing stage with Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified contract…

Monday May 24, 2021 - 1:31 pm

InvestorNewsBreaks – United Medical Equipment Business Solutions Network Inc. Tailoring Solutions to Customers’ Needs, Budget

United Medical Equipment (“UME,” “UMEBSNI”) is playing a vital role in making it possible for businesses and health care facilities to maintain safety and health among employees and customers by supplying personal protective equipment (“PPE”) and rapid antibody test kits. UME’s contribution is essential now more than ever due to factors such as the uncertainty surrounding the ability of the vaccines to suppress the spread…

Monday May 24, 2021 - 10:01 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Secures Purchase Order for Its Pediatric NeuroCap(TM) EEG Headsets

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, today announced that Maine Medical Center has placed an order for a limited supply of the company’s pediatric NeuroCap(TM) disposable EEG caps for use with its pediatric patients. Maine Medical Center, with a staff of over 6,000, is a 637-licensed-bed teaching hospital for Tufts University School of Medicine. “We are happy to provide our…

Thursday May 20, 2021 - 12:17 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leverages Key Initiatives to Advance Drug Candidates

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs. “Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (‘PFN’(TM)) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas,” reads a recent article regarding Tryp’s positioning. The piece also discusses the company’s…

Thursday May 20, 2021 - 10:58 am

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Presentation Schedule for June Investor Conferences

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will present at two investor conferences slated to take place in June. These include scheduled presentations, as detailed in the update, at the Jefferies Virtual Healthcare Conference and the William…

Wednesday May 19, 2021 - 2:46 pm

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Is Pushing Boundaries of What Is Possible in Neurology Research

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, was recently featured in Neoscope (a publication by Futurism) as a company that champions cutting-edge research that is shaping the future in the field of brain diagnostics. “The article details Brain Scientific’s e-tattoo technology — a series of tiny electrodes stitched beneath the skin that can get a clear reading of…

Wednesday May 19, 2021 - 10:11 am

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Announces On-Track Progress for Demonstration of i/Blue Imaging System(TM)

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging. Per the update, the company is on target to demonstrate the i/Blue Imaging System(TM) in private meetings during the American Urology Association (“AUA”) meeting to be held in early…

Tuesday May 18, 2021 - 3:14 pm

InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CTO Discusses Revolutionizing Drug Discovery in Bell2Bell Podcast

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent episode of The Bell2Bell Podcast. Predictive Oncology’s newly appointed CEO Mel Engle, CFO Bob Myers and Mark Collins, chief technical officer of the company’s Helomics subsidiary, joined the program to share financial updates, future goals and insight into current operations. The…

Tuesday May 18, 2021 - 3:01 pm

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Eyes ‘Exceptional’ Work to Move i/Blue Imaging System(TM) into Commercial Manufacturing

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, was featured in a recent article that discussed its timely progress toward 2022 completion of its innovative i/Blue Imaging System(TM). The patented system is designed leveraging proprietary light sensors and optics to improve the efficiency and accuracy of bladder cancer visualization and removal. According to the update, the on-track progress can be largely attributed to…

Friday May 14, 2021 - 1:40 pm

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Focuses ‘Covid-ID Lab’ Commercialization Strategy Initially on German Market

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently entered a strategic distribution, storage and logistics agreement for its commercial 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”). In April, XPhyto announced its entry into the agreement with a full-fledged German pharmaceutical wholesaler and service provider. Under the agreement, the German partner will distribute, store and deliver Covid-ID Lab test kits to…

Friday May 14, 2021 - 12:39 pm

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Collaborating to Potentially Uncover Innovative New Treatment Options

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, recently began a collaboration with JelikaLite in a clinical trial. The clinical trial, which has 30 participants from two New York City locations, is designed to potentially uncover new treatment options to reduce autism symptoms in children. “JelikaLite was launched by medical researchers and practitioners specializing in psychology, neurology and phototherapy.…

Wednesday May 12, 2021 - 12:48 pm

InvestorNewsBreaks – Healthy Extracts Inc. (HYEX) Poised for Opportunity in Burgeoning Global Health Products Sector

Healthy Extracts (OTCQB: HYEX) is well-positioned to capitalize further on the rapidly growing health products market, which has already positively impacted the company. “The increasing interest, which has led to more demand for the products, has positively impacted HYEX, as evidenced by the company’s improved revenue from $748,377 in 2019 to $1,276,559 in 2020, representing a 71% jump,” reports a recent article. Healthy Extracts wholly…

Tuesday May 11, 2021 - 10:29 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Q2 Virtual Investor Summit

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its CEO John Climaco will present at the Q2 Virtual Investor Summit at 12:30 p.m. ET on Tuesday, May 18. In addition to the presentation, CNS management will be available to participate in virtual one-on-one meetings…

Tuesday May 11, 2021 - 9:20 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) CEO Talks Business in Two Video Interviews

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) director and CEO Hugh Rogers was a featured guest on two different video interviews. In both interviews, Rogers shared key information and updates about XPhyto, a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. During his InvestorIntel interview with host Peter Clausi, Rogers mentioned that the company had recently received European…

Monday May 10, 2021 - 2:21 pm

InvestorNewsBreaks – United Medical Equipment Business Solutions Network Inc. Continues Vital Role in Dealing with COVID-19

United Medical Equipment (“UME,” “UMEBSNI”) has, from the beginning of the COVID-19 pandemic, been at the forefront of addressing various emerging needs. “The company acted as a trusted senior referral source for senior care living communities such as independent and assisted living, hospice and memory care,” reads a recent article. “UME also supplied personal protective equipment (‘PPE’) with flexible payment options and provided comprehensive telehealth.”…

Monday May 10, 2021 - 9:32 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Master Agreement with Leading CRO Clinlogix

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered into a master service agreement with Clinlogix, a contract research organization (“CRO”). The agreement is a key step for initiating and supporting the clinical development of Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program. Tryp noted that Clinlogix has global experience in providing CRO services…

Friday May 07, 2021 - 3:32 pm

InvestorNewsBreaks – RYAH Group Inc. Bringing Innovative Tech Solutions to Plant-Based Treatment Market

RYAH Group, a company developing proprietary technology supporting a data-driven approach to health care, understands the value of combining data with analytics, as reflected by the fact that its products merge these two fundamental elements. “The company has created unique products that pair a growing ecosystem of therapeutic plants with top-rated apps, devices and services,” reads a recent article. “RYAH’s easy-to-operate line of products help…

Friday May 07, 2021 - 3:29 pm

InvestorNewsBreaks – Brain Scientific Inc.’s (BRSF) Products Designed to Disrupt EEG Market

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, has sought to narrow the wide access-to-neurological-care gap through portable EEGs, teleneurology, on-demand data exchange and AI predictive biomarkers. “By creating cost-efficient, disposable and portable EEGs, BRSF makes neurology care more accessible without putting excess strain on the already overextended neurologist labor pool,” reads a recent article. As a result, the…

Friday May 07, 2021 - 3:07 pm

InvestorNewsBreaks – Healthy Extracts Inc. (HYEX) Leads Research and Manufacture of Beneficial Plant-Based Formulations

Healthy Extracts (OTCQB: HYEX) has continued to strengthen its stronghold in the health and lifestyle industry by researching and manufacturing plant-based formulations offering supplements that are beneficial for heart and nerve health. HYEX has broadened its portfolio through acquisitions of unique assets, BergaMet North America and Ultimate Brain Nutrients (“UBN”). “Healthy Extracts Inc. recently announced positive results of clinical studies for two leading products: BergaMet…

Friday May 07, 2021 - 1:30 pm

InvestorNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) i/Blue(TM) Imaging System to Enable More Accurate Tumor Resection

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has made notable strides in its quest to offer innovative technology for visualizing cancer. Designed to address the limitations of both white and blue light cystoscopy procedures, IME’s i/Blue(TM) Imaging System displays real-time white and blue light images on the screen simultaneously. This eliminates the need for the surgeon to switch back and forth between…

Friday May 07, 2021 - 11:36 am

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference/Webcast to Discuss Q1 Results, Provide Clinical Pipeline Update

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that it will host a conference call and live webcast to discuss its first quarter 2021 results and provide an update on its clinical pipeline. The event is scheduled to take place at 5:30 p.m. ET on Thursday,…

Friday May 07, 2021 - 10:28 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Launches ‘Covid-ID Lab’ POC Pilot Project in Germany

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its commencement of a pilot project with its rapid COVID-19 PCR test ("Covid-ID Lab") in a point-of-care ("POC") setting in Germany. Covid-ID Lab was recently approved in Europe and offers the accuracy of a PCR test in only 25 minutes. Validated work flows, including mobile collection and processing of patient samples, will be further optimized…

Thursday May 06, 2021 - 2:47 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Advancing Solutions for ‘Personalized Medicine at Its Finest’

Predictive Oncology (NASDAQ: POAI) has made several advances in providing cancer treatment solutions. Its subsidiary, TumorGenesis, “specializes in technology that preserves a patient’s unique cancer tissue biological signatures, thereby allowing researchers to study cancer in the laboratory using samples that reflect actual tumors found in a patient,” reads a recent article. TumorGenesis’ transformational technology enables cell lines from patients to represent more than 90% of…

Thursday May 06, 2021 - 10:20 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured on Gamechangers LIVE

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) was featured in a recent episode of Gamechangers LIVE, a podcast series that shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. XPhyto Therapeutics’ CEO and Director, Hugh Rogers, joined the broadcast, hosted by Executive Coach and…

Wednesday May 05, 2021 - 10:15 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Centralized IRB Approval for Acclaim-1 Clinical Trial

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its receipt of centralized Institutional Review Board (“IRB”) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung cancer (“NSCLC”). Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines the company’s lead drug candidate, REQORSA(TM) immunogene…

Tuesday May 04, 2021 - 11:18 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Acclaim-2 Clinical Trial

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). An open-label, multicenter Phase 1/2 clinical trial, Acclaim-2 combines Genprex’s lead drug candidate, REQORSA(TM) immunogene therapy, with Merck & Co Inc.’s Keytruda…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions